PRCT Stock Analysis: Procept Biorobotics | NASDAQ

Medical Devices | NASDAQ, USA | Market Cap: 1.197m USD | 12M Return: -64.7% | Charts, Fundamentals & Technical Analysis

Surgical Robotics, Aquablation Therapy, Urology Systems, BPH Treatment
Total Rating 20
Safety 66
Buy Signal -0.79
Medical Devices
Industry Rotation: +0.0
Market Cap: 1.20B
Avg Turnover: 39.2M
Risk 3d forecast
Volatility60.4%
VaR 5th Pctl9.79%
VaR vs Median-1.55%
Reward TTM
Sharpe Ratio-1.41
Rel. Str. IBD2.9
Rel. Str. Peer Group5.2
Character TTM
Beta1.184
Beta Downside1.396
Hurst Exponent0.392
Drawdowns 3y
Max DD80.14%
CAGR/Max DD-0.21
CAGR/Mean DD-0.51
EPS (Earnings per Share) EPS (Earnings per Share) of PRCT over the last years for every Quarter: "2021-06": -0.41, "2021-09": -0.32, "2021-12": -0.42, "2022-03": -0.39, "2022-06": -0.43, "2022-09": -0.51, "2022-12": -0.56, "2023-03": -0.63, "2023-06": -0.56, "2023-09": -0.51, "2023-12": -0.54, "2024-03": -0.51, "2024-06": -0.5, "2024-09": -0.4, "2024-12": -0.35, "2025-03": -0.45, "2025-06": -0.35, "2025-09": -0.38, "2025-12": -0.53, "2026-03": -0.56,
Last SUE: 0.00
Qual. Beats: 0
Revenue Revenue of PRCT over the last years for every Quarter: 2021-06: 8.476, 2021-09: 8.668, 2021-12: 10.138, 2022-03: 14.197, 2022-06: 16.691, 2022-09: 20.349, 2022-12: 23.777, 2023-03: 24.404, 2023-06: 33.104, 2023-09: 35.102, 2023-12: 43.581, 2024-03: 44.539, 2024-06: 53.353, 2024-09: 58.37, 2024-12: 68.236, 2025-03: 69.162, 2025-06: 79.182, 2025-09: 83.327, 2025-12: 76.383, 2026-03: 83.132,
Rev. CAGR: 54.15%
Rev. Trend: 98.8%
Last SUE: 0.28
Qual. Beats: 0

Warnings

Interest Coverage Ratio Critical
Choppy
Below Sma 200d

Tailwinds

No distinct edge detected

Seasonality 4.8 years of data

Jan -5.3% 22
Feb -9.8% 47
Mar -7.3% 21
Apr +2.0% 21
May +13.5% 57
Jun -6.1% 23
Jul -2.5% 35
Aug +0.8% 11
Sep -1.6% 37
Oct +4.3% 25
Nov +1.3% 0
Dec +0.5% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: PRCT Procept Biorobotics

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) is a surgical robotics company focused on urology, developing, manufacturing, and selling image-guided robotic systems for the treatment of benign prostatic hyperplasia (BPH). Its flagship product, the AquaBeam Robotic System, enables minimally invasive urologic surgery using Aquablation therapy, a heat-free waterjet-based approach that ablates prostate tissue without the thermal risks associated with traditional laser or electrocautery methods. The company also offers the HYDROS Robotic System, which delivers image-guided Aquablation therapy for men suffering from lower urinary tract symptoms (LUTS) caused by BPH.

Founded in 2007 and headquartered in San Jose, California, PROCEPT BioRobotics went public on September 15, 2021, and operates within the Health Care Equipment sub-industry. The company sells its systems in both the United States and international markets, serving a large and growing patient population as BPH is a highly prevalent condition among aging men. Its business model centers on capital equipment sales combined with recurring revenue from procedure-based consumables used during each Aquablation treatment.

Headlines to Watch Out For
  • Aquablation procedure volume accelerates across US hospital systems
  • Gross margin expansion drives path to profitability
  • Hospital capital spending pressure limits new system placements
  • Competition intensifies from alternative BPH treatment options
Piotroski VR-10 (Strict) 1.5
Net Income: -102.5m TTM > 0 and > 6% of Revenue
FCF/TA: -0.17 > 0.02 and ΔFCF/TA 0.44 > 1.0
NWC/Revenue: 113.2% < 20% (prev 165.9%; Δ -52.75% < -1%)
CFO/TA -0.14 > 3% & CFO -70.1m > Net Income -102.5m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 6.73 > 1.5 & < 3
Outstanding Shares: last quarter (56.5m) vs 12m ago 2.90% < -2%
Gross Margin: 62.98% > 18% (prev 62.71%; Δ 0.27% > 0.5%)
Asset Turnover: 63.99% > 50% (prev 47.97%; Δ 16.03% > 0%)
Interest Coverage Ratio: -28.01 > 6 (EBIT TTM -98.8m / Interest Expense TTM 3.53m)
Altman Z'' 1.70
A: 0.75 (Total Current Assets 428.0m - Total Current Liabilities 63.6m) / Total Assets 487.1m
B: -1.38 (Retained Earnings -673.2m / Total Assets 487.1m)
C: -0.20 (EBIT TTM -98.8m / Avg Total Assets 503.2m)
D: 2.49 (Book Value of Equity 347.7m / Total Liabilities 139.4m)
Altman-Z'' = 1.70 = BBB
Beneish M -2.59
DSRI: 0.94 (Receivables 96.4m/79.3m, Revenue 322.0m/249.1m)
GMI: 1.00 (GM 62.71% / 62.98%)
AQI: 1.48 (AQ_t 0.02 / AQ_t-1 0.01)
SGI: 1.29 (Revenue 322.0m / 249.1m)
TATA: -0.07 (NI -102.5m - CFO -70.1m) / TA 487.1m)
Beneish M = -2.59 (Cap -4..+1) = A
What is the price of PRCT shares?

As of July 11, 2026, the stock is trading at USD 20.89 with a total of 1,207,660 shares traded. Over the past week, the price has changed by -0.67%, over one month by -28.19%, over three months by -9.96% and over the past year by -64.72%.

Current recommended Stop Loss: 18.80 (which is 10% or 1.3 ATR below the current price).

Is PRCT a buy, sell or hold?

Procept Biorobotics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy PRCT.

  • StrongBuy: 6
  • Buy: 1
  • Hold: 4
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the PRCT price?
Analysts Target Price 29.7 42.2%
Procept Biorobotics (PRCT) - Fundamental Data Overview as of 07 July 2026
Market Cap USD = 1.20b (1.20b USD * 1.0 USD.USD)
P/S = 3.7171
P/B = 3.4438
Revenue TTM = 322.0m USD
EBIT TTM = -98.8m USD
EBITDA TTM = -92.1m USD
Long Term Debt = 51.7m USD (from longTermDebt, last quarter)
 Short Term Debt = unknown (none)
 Debt = 78.0m USD (from shortLongTermDebtTotal, last quarter) + Leases 26.3m
Net Debt = -167.6m USD (calculated: Debt 78.0m - CCE 245.6m)
Enterprise Value = 1.03b USD (1.20b + Debt 78.0m - CCE 245.6m)
Interest Coverage Ratio = -28.01 (Ebit TTM -98.8m / Interest Expense TTM 3.53m)
EV/FCF = -12.78x (Enterprise Value 1.03b / FCF TTM -80.6m)
FCF Yield = -7.83% (FCF TTM -80.6m / Enterprise Value 1.03b)
FCF Margin = -25.02% (FCF TTM -80.6m / Revenue TTM 322.0m)
Net Margin = -31.82% (Net Income TTM -102.5m / Revenue TTM 322.0m)
Gross Margin = 62.98% ((Revenue TTM 322.0m - Cost of Revenue TTM 119.2m) / Revenue TTM)
Gross Margin QoQ = 64.89% (prev 60.63%)
Tobins Q-Ratio = 2.11 (Enterprise Value 1.03b / Total Assets 487.1m)
Interest Expense / Debt = 4.52% (Interest Expense 3.53m / Debt 78.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -78.0m (EBIT -98.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 6.73 (Total Current Assets 428.0m / Total Current Liabilities 63.6m)
Debt / Equity = 0.22 (Debt 78.0m / totalStockholderEquity, last quarter 347.7m)
 Debt / EBITDA = 1.82 (negative EBITDA) (Net Debt -167.6m / EBITDA -92.1m)
 Debt / FCF = 2.08 (negative FCF - burning cash) (Net Debt -167.6m / FCF TTM -80.6m)
 Total Stockholder Equity = 369.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.36% (Net Income -102.5m / Total Assets 487.1m)
RoE = -27.70% (Net Income TTM -102.5m / Total Stockholder Equity 369.9m)
RoCE = -23.43% (EBIT -98.8m / Capital Employed (Equity 369.9m + L.T.Debt 51.7m))
 RoIC = -19.15% (negative operating profit) (NOPAT -78.0m / Invested Capital 407.3m)
 WACC = 9.75% (E(1.20b)/V(1.27b) * Re(10.15%) + D(78.0m)/V(1.27b) * Rd(4.52%) * (1-Tc(0.21)))
Discount Rate = 10.15% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 5.04%
 [DCF] Fair Price = unknown (Cash Flow -80.6m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.78 | Revenue CAGR: 54.15% | SUE: 0.28 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.46 | Chg30d=-0.22% | Revisions=-25% | Analysts=10
EPS next Quarter (2026-09-30): EPS=-0.34 | Chg30d=+0.00% | Revisions=-25% | Analysts=10
EPS current Year (2026-12-31): EPS=-1.53 | Chg30d=-1.10% | Revisions=+0% | GrowthEPS=+10.9% | GrowthRev=+29.0%
EPS next Year (2027-12-31): EPS=-0.88 | Chg30d=-1.10% | Revisions=-25% | GrowthEPS=+42.9% | GrowthRev=+23.4%
[Analyst] Revisions Ratio: -38% (up=1, down=4)